NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

Yet another study on HPD.
This one from Korea.

https://www.ncbi.nlm.nih.gov/pubmed/30977778

It demonstrated that 20% of advanced/metastatic NSCLC patients experienced hyper-progressive after PD-1/PDL-1 treatment, with associated worsening of PFS and OS.
263 patients over 4.5 years were studied.

They concluded:-

HPD is common in NSCLC patients treated with PD-1/PD-L1 inhibitors. Biomarkers derived from rationally designed analysis may successfully predict HPD and worse outcomes, meriting further investigation of HPD.

You can be sure that the same sort of incidence is occurring all over the world, but it is concealed in the US.

That's 20% who have a horrible accelerated death from a supposed treatment..